Finance

Lists
Why is AAPG down 3,10%?
Dive Deeper
AAPG:NASDAQ
Ascentage Pharma Group Internatinl - ADR
12,61 USD
-3,10%
(-0,40) 1D
19-ноя., 13:12:46 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AAPG...
Open
12,61 USD
High
12,61 USD
Low
12,50 USD
Mkt. cap
1,15 млд
Avg. vol.
7,48 миң
Volume
1,06 миң
52-wk high
32,96 USD
52-wk low
12,50 USD
EPS
-2,37 USD
Shares outstanding
93,74 млн
No. of employees
828
Open
12,61 USD
High
12,61 USD
Low
12,50 USD
Mkt. cap
1,15 млд
Avg. vol.
7,48 миң
Volume
1,06 миң
52-wk high
32,96 USD
52-wk low
12,50 USD
EPS
-2,37 USD
Shares outstanding
93,74 млн
No. of employees
828
News stories
From web sources and news partners
About Ascentage Pharma Group Internatinl - ADR
CEODajun Yang
Employees828
Founded2009
Headquarters-
SectorHealth Care
Industry-
Analyst ratings
Based on 7 analysts giving stock ratings to AAPG in the past 3 months
Strong buy
Buy
7
Hold
0
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for AAPG in the last 3 months.
Highest
Current 12,61 USD
48,00 USD (+280,65%)
Average
42,00 USD (+233,07%)
Lowest
33,00 USD (+161,70%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jeet Mukherjee
BTIG
Buy
Maintained
48,00 USD
+280,7%
11/05/2026
Yigal Nochomovitz
Citi
Buy
Initiated
46,00 USD
+264,8%
10/15/2026
Silvan Turkcan
Citizens JMP
Buy
Initiated
35,00 USD
+177,6%
10/13/2026
Brian Cheng
J.P. Morgan
Buy
Maintained
33,00 USD
+161,7%
10/08/2026
Mayank Mamtani
B. Riley Securities
Buy
Maintained
45,00 USD
+256,9%
09/02/2026
Gregory Renza
Truist Financial
Buy
Maintained
-
-
08/21/2026
Jeff Jones
Oppenheimer
Buy
Maintained
45,00 USD
+256,9%
08/21/2026
Biren Amin
Piper Sandler
Buy
Maintained
48,00 USD
+280,7%
06/01/2026
James Shin
Deutsche Bank
Buy
Initiated
40,00 USD
+217,2%
04/24/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
45,00 USD
+256,9%
03/27/2026
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
170,21 млн
170,21 млн
151,11 млн
151,11 млн
Cost of goods sold
13,64 млн
13,64 млн
5,86 млн
5,86 млн
Cost of revenue
13,64 млн
13,64 млн
5,86 млн
5,86 млн
Research and development expenses
304,44 млн
304,44 млн
348,73 млн
348,73 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
181,22 млн
181,22 млн
172,64 млн
172,64 млн
Operating expense
485,67 млн
485,67 млн
521,37 млн
521,37 млн
Total operating expenses
499,31 млн
499,31 млн
527,23 млн
527,23 млн
Operating income
-329,10 млн
-329,10 млн
-376,13 млн
-376,13 млн
Other non operating income
-2,99 млн
-2,99 млн
-30,14 млн
-30,14 млн
EBT including unusual items
-325,37 млн
-325,37 млн
-401,69 млн
-401,69 млн
EBT excluding unusual items
-324,79 млн
-324,79 млн
-401,69 млн
-401,69 млн
Income tax expense
714,00 миң
714,00 миң
6,81 млн
6,81 млн
Effective tax rate
-0,22%
-0,22%
-1,70%
-1,70%
Other operating expenses
-
-
-
-
Net income
-326,00 млн
-326,00 млн
-408,35 млн
-408,35 млн
Net profit margin
-191,53%
-191,53%
-270,24%
-270,24%
Earnings per share
-
-
-
-
Interest and investment income
25,36 млн
25,36 млн
18,00 млн
18,00 млн
Interest expense
-13,14 млн
-13,14 млн
-13,41 млн
-13,41 млн
Net interest expenses
12,22 млн
12,22 млн
4,59 млн
4,59 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-310,96 млн
-310,96 млн
-356,97 млн
-356,97 млн
Gain or loss from assets sale
-333,50 миң
-333,50 миң
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google колдонмолору